DMP1 and hyperparathyroidism: These effects, combined with DMP1 inhibitory effects on FGF23 transcription, lead to less severe elevations of circulating FGF23 levels and positive effects on cardiac health and survival (Fig. 7), despite persistent kidney disease, hypertension, hyperphosphatemia, and hyperparathyroidism.